Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity.
The application of effective chemotherapy protocols in companion animals with sensitive tumors may result in return to a good quality of life and extended long-term survival. However, the potential for adding adverse events that impact overall quality of life in veterinary cancer patients is an important consideration. To ensure the experience is a positive one for our clients and patients alike, the practicing veterinary oncologist must ensure clients are appropriately educated as to the type and likelihood of adverse events that may occur in their companions and should plan for appropriate preventative and therapeutic protocols to manage them. Such attention to detail will help guarantee their clients' experience with medical treatment is positive and worthwhile, and will result in improvement in the well-being of their companion.
Vail
David M
DM
University of Wisconsin-Madison, School of Veterinary Medicine, Madison, WI 53706, USA. vaild@svm.vetmed.wisc.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000628:therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000662:veterinary*; D009503:Neutropenia / Q000139:chemically induced* / Q000628:therapy
D000970:Antineoplastic Agents